natalizumab (tysabri) Report issue

Biologics mAb Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in multiple sclerosis.   Wikipedia

More Chemistry

Drug Pricing (per unit)

Australia

$1039.4292

United States

$4138.5900 - $5773.6800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

an100226m | antegran | antegren | anti-alpha4 integrin | anti-vla4 | natalizumab | tysabri

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue